Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age

SARS-CoV2 or CoVid19 disease is a newly described pathology linked to a subtype of the coronavirus family identified in China in December 2019. This pathology can present multiple clinical facets, ranging from asymptomatic forms to more commonly critical pulmonary forms called "Acute Respiratory Distress Syndrome". The elderly population is more at risk for this infection due to the senescence of the immune system, co-morbidities and poly medications. They also often present a greater state of fragility.

This study aims to report the epidemiology of the first 50 patients over 90 years of age hospitalized within the CHU Brugmann hospital.

Study Overview

• Status: Completed
• Conditions: Covid19
• Intervention / Treatment: Other: Data collection from medical files

• Study Type: Observational
• Enrollment (Actual): 50

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium
    • CHU Brugmann

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 90 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Same as inclusion criteria

Description

Inclusion Criteria:

• Be over 90 years of age on the date of admission to CHU Brugmann Hospital
• Have a SARS Cov2 infection proven by antigen or RT-PCR on smear and / or typical imaging regardless of the clinical manifestation
• Have been hospitalized at CHU Brugmann between 03/01/2020 and 05/10/2020

Exclusion Criteria:

None

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Covid positive; Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection.	Other: Data collection from medical files; Data collection from medical files
Sub-group: deceased patients; Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, with death as outcome.	Other: Data collection from medical files; Data collection from medical files
Sub-group: patients who survived; Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, who survived the infection.	Other: Data collection from medical files; Data collection from medical files

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demographic data	Age, sex, ethnicity	5 minutes
Comorbidities	Smoking, Obesity, Diabetes, Arterial hypertension, Coronary pathology, Cerebrovascular disease, chronic renal failure, chronic obstructive pulmonary disease, Neoplasia, Autoimmune disease, Chronic liver disease	5 minutes
Cumulative Illness Rating Scale-Geriatric (CIRS-G)	CIRS-G quantifies burden of disease in elderly patients (comorbidity scale). Higher scores indicate higher severity (maximum score = 56 points).	5 minutes
Treatments	Under Chronic corticosteroid therapy or Immunosuppressive therapy	5 minutes
Signs and symptoms	Presence and date of first apparition: Fever, Cough, Dyspnea, Chest pain, Nausea or vomiting, Diarrhea, Fatigue, Anosmia, ageusia, inappetence, Confusion, Fall, Fracture	5 minutes
Fever	Vital signs at hospital admission: Fever	5 minutes
Hypoxemia	Vital signs at hospital admission: Hypoxemia	5 minutes
Tachycardia	Vital signs at hospital admission:Tachycardia	5 minutes
Hypotension	Vital signs at hospital admission: Hypotension	5 minutes
Gasometry	Vital signs at hospital admission: Gasometry	5 minutes
Infectious data	Contact with confirmed covid person before admission, lives in a retirement home with other cases, Initial bacterial or viral co-infection, Bacterial or viral co-infection during the hospital stay	5 minutes
Blood count	Blood count at hospital admission or first recorded	5 minutes
Ionogram	Ionogram at hospital admission or first recorded	5 minutes
Liver function	Liver function at hospital admission or first recorded	5 minutes
Coagulation	Coagulation at hospital admission or first recorded	5 minutes
Renal function	Renal function at hospital admission or first recorded	5 minutes
Albumin	Albumin at hospital admission or first recorded	5 minutes
CRP	CRP at hospital admission or first recorded	5 minutes
Fibrinogen	Fibrinogen at hospital admission or first recorded	5 minutes
D-dimers at hospital admission or first recorded	D-dimers	5 minutes
NTproBNP	NTproBNP at hospital admission or first recorded	5 minutes
CK	CK at hospital admission or first recorded	5 minutes
Troponin	Troponin at hospital admission or first recorded	5 minutes
Ferritin	Ferritin at hospital admission or first recorded	5 minutes
Procalcitonin	Procalcitonin at hospital admission or first recorded	5 minutes
Biology - highest rate	Highest rate of CRP, D-Dimers, Urea, Creatinin, Fibrinogen, CK, Troponins	5 minutes
Biology - lowest rate	Lowest rate of hemoglobin, platelets, leucocytes, lymphocytes, albumin, Na+, K+	5 minutes
Percentage of pulmonary involvement on chest CT scan	Percentage of pulmonary involvement on chest CT scan	5 minutes
Number of pulmonary lobes affected	Number of pulmonary lobes affected	5 minutes
Type of lesions	Type of lesions as reflected on the CT scan images: 'Ground glass' or 'Crazy paving'	5 minutes
Need for oxygenotherapy	Need for oxygenotherapy (yes/no)	5 minutes
Means of ventilation	Means of ventilation	5 minutes
Treatment received	Hydroxychloroquine or Azithromycin	5 minutes
Length of ICU Stay	Length of ICU Stay	5 minutes
Status at hospital exit	One of the following choices: death, went back home, went back to a retirement home, was placed in a revalidation unit.	5 minutes
Mortality	28-day mortality after PCR / CT scan / diagnosis	5 minutes

Collaborators and Investigators

• Sponsor: Murielle Surquin

Study record dates

Study Major Dates

• Study Start (Actual): June 9, 2020
• Primary Completion (Actual): November 23, 2020
• Study Completion (Actual): November 23, 2020

Study Registration Dates

• First Submitted: August 3, 2020
• First Submitted That Met QC Criteria: August 4, 2020
• First Posted (Actual): August 5, 2020

Study Record Updates

• Last Update Posted (Actual): March 29, 2022
• Last Update Submitted That Met QC Criteria: March 28, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: CHUB-COVID-19-90+

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No